AI Agent Development in Boston, Massachusetts

Biotech / Pharmaceutical Research

A Cambridge-based biotech company (developing mRNA-based therapeutics for rare genetic diseases, 280 employees, 3 active clinical programs, pre-revenue with $420M raised across Series A-D) had a literature review bottleneck that was slowing research decisions across all three clinical programs. The research team of 45 scientists conducted systematic literature reviews for: target identification (identifying potential therapeutic targets based on published genetic, proteomic, and clinical data), competitive landscape analysis (monitoring competitor programs, published trial results, and regulatory decisions), safety signal evaluation (reviewing published adverse event data relevant to their therapeutic targets and delivery mechanisms), and regulatory precedent research (finding FDA precedent decisions relevant to their regulatory strategy). Each systematic review required 3-8 weeks of a senior researcher's time — searching PubMed (36M+ articles), Semantic Scholar, BioRxiv/MedRxiv preprints, ClinicalTrials.gov, FDA advisory committee transcripts, and patent databases; screening thousands of results for relevance; extracting key findings; and synthesizing a report with citations. The company conducted 40-60 literature reviews per year, consuming approximately 8,000 researcher-hours annually — the equivalent of 4 full-time senior researchers doing nothing but literature review. More critically, the lead time for literature reviews delayed research decisions. When a clinical observation required rapid literature assessment (a potential safety signal observed in a Phase 2 trial requiring immediate evaluation of prior published evidence), the 3-8 week timeline was incompatible with the clinical urgency.

We built a specialized literature research agent over 14 weeks, designed for the specific requirements of mRNA therapeutics research. The agent operated as an autonomous research assistant that could execute multi-database literature searches, screen results for relevance, extract structured data from relevant papers, and generate synthesized reports with full citations — tasks that previously required weeks of senior researcher time. Knowledge Integration: the agent accessed 6 data sources through API integrations: PubMed (via NCBI E-utilities API — full access to 36M+ biomedical citations), Semantic Scholar (academic paper search with citation graph navigation), BioRxiv/MedRxiv (preprint servers for the latest unpublished research), ClinicalTrials.gov (clinical trial registrations, results, and adverse events), FDA (advisory committee transcripts, approval letters, and guidance documents via FDA API), and the company's internal research database (Electronic Lab Notebook data, internal reports, and previous literature reviews stored in a Confluence-based knowledge base). Search Strategy Agent: rather than simple keyword search, the agent constructed multi-faceted search strategies mimicking how an experienced researcher approaches systematic review. For a target identification query, the agent: generated a search taxonomy (MeSH terms, gene names, protein names, pathway identifiers, and disease ontology terms relevant to the research question), executed parallel searches across all 6 databases with source-appropriate query syntax, deduplicated results across sources (the same paper often appears in PubMed, Semantic Scholar, and preprint servers), and ranked results using a relevance scoring model fine-tuned on the company's historical literature review assessments (which papers their researchers had previously flagged as highly relevant for similar queries). Screening Agent: the relevance scoring model replaced the manual screening step — reading titles and abstracts of thousands of search results to identify the 50-200 that warranted full-text review. The model was fine-tuned on 12,000 researcher screening decisions from previous reviews (papers marked "include" or "exclude" with researcher notes explaining the decision). For edge cases (relevance score between 40-70%), the agent flagged papers for human review rather than making an autonomous include/exclude decision. Extraction Agent: for papers that passed screening, the agent extracted structured data: study type (in vitro, in vivo, clinical), therapeutic target, mechanism of action, patient population (for clinical studies), efficacy endpoints and results, safety findings (adverse events, dose-limiting toxicities), and delivery mechanism details (particularly relevant for mRNA therapeutics where the lipid nanoparticle delivery system significantly affects efficacy and safety). Synthesis Agent: the final agent component generated a structured literature review report: executive summary (key findings in 2-3 paragraphs), detailed findings organized by the researcher's specific questions, evidence quality assessment (rating the strength of evidence for each finding based on study design, sample size, and publication venue), knowledge gaps identification (areas where the published literature does not adequately address the research question), and complete citation list with direct links to each paper. Every claim in the report was linked to its source citation — and the synthesis agent was explicitly instructed to distinguish between findings supported by multiple studies, single-study findings, and areas of conflicting evidence.

Literature review completion time decreased from 3-8 weeks to 2-4 days for standard reviews. Emergency literature assessments (safety signal evaluation during active clinical trials) could be completed in 4-8 hours — compared to the previous minimum of 1-2 weeks even when a researcher dropped everything to focus exclusively on the review. The agent's search coverage exceeded manual search coverage — in a head-to-head comparison on 5 historical reviews, the agent identified an average of 23% more relevant papers than the human researchers had found, primarily from preprint servers, FDA advisory committee transcripts, and cross-disciplinary sources that researchers had not included in their manual search strategies. Screening accuracy: the agent correctly classified 91% of papers at the include/exclude threshold (compared against senior researcher validation). The 9% error rate broke down as: 6% false negatives (papers incorrectly excluded — mitigated by the edge-case flagging system that caught most of these) and 3% false positives (papers incorrectly included — a low-cost error since human reviewers would catch these during full-text review). The company reallocated approximately 6,000 researcher-hours annually from literature review to higher-value research activities — hypothesis generation, experimental design, and data interpretation. The Chief Scientific Officer estimated that the agent accelerated the research decision cycle by an average of 3 weeks per decision, which across the company's 3 active clinical programs and 2 preclinical programs represented a cumulative 6-9 month acceleration in the overall research timeline. At the company's stage ($420M raised, pre-revenue, burning $15M/month), 6-9 months of timeline acceleration represented $90-135M in reduced cash burn to key milestones. Development cost: $195,000 (14 weeks). Annual infrastructure: $36,000 (API costs, compute, storage). First-year value: researcher time recovery ($720,000 at loaded cost) + timeline acceleration (conservatively $10-15M in reduced burn to milestone, though attributing this precisely to the literature agent alone is approximate). ROI: on researcher time alone, 269%. Including timeline acceleration impact, the ROI is orders of magnitude higher.